Jane Street Group LLC Invests $81,000 in Compugen Ltd. (NASDAQ:CGEN)

Jane Street Group LLC bought a new stake in shares of Compugen Ltd. (NASDAQ:CGEN) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 53,030 shares of the biotechnology company’s stock, valued at approximately $81,000. Jane Street Group LLC owned about 0.06% of Compugen as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Commonwealth Equity Services LLC purchased a new position in shares of Compugen in the fourth quarter worth $32,000. Oppenheimer & Co. Inc. grew its holdings in Compugen by 187.3% in the 4th quarter. Oppenheimer & Co. Inc. now owns 55,602 shares of the biotechnology company’s stock worth $85,000 after acquiring an additional 36,252 shares during the last quarter. Raymond James Financial Inc. purchased a new position in shares of Compugen in the fourth quarter valued at about $103,000. Marshall Wace LLP raised its stake in shares of Compugen by 84.9% during the fourth quarter. Marshall Wace LLP now owns 88,169 shares of the biotechnology company’s stock valued at $135,000 after acquiring an additional 40,494 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. boosted its holdings in shares of Compugen by 15.7% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 317,500 shares of the biotechnology company’s stock worth $486,000 after purchasing an additional 43,165 shares during the period. Hedge funds and other institutional investors own 12.22% of the company’s stock.

Compugen Stock Up 1.8%

Shares of Compugen stock opened at $1.74 on Monday. The business has a 50 day moving average of $1.41 and a 200 day moving average of $1.68. Compugen Ltd. has a 52 week low of $1.13 and a 52 week high of $2.66. The company has a market cap of $155.27 million, a PE ratio of 87.00 and a beta of 2.54.

Compugen (NASDAQ:CGEN) last issued its quarterly earnings data on Monday, May 19th. The biotechnology company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Compugen had a return on equity of 2.62% and a net margin of 2.67%. The company had revenue of $2.28 million during the quarter, compared to the consensus estimate of $3.70 million. During the same quarter last year, the company posted ($0.08) earnings per share. On average, research analysts anticipate that Compugen Ltd. will post -0.03 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen downgraded Compugen from a “buy” rating to a “hold” rating in a report on Wednesday, March 5th.

About Compugen

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.